Document:

THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED,
OR ANY STATE SECURITIES LAWS, AND MAY NOT BE TRANSFERRED UNLESS THE COMPANY HAS RECEIVED A WRITTEN OPINION FROM COUNSEL IN FORM
AND SUBSTANCE SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSFER IS BEING MADE IN COMPLIANCE WITH ALL APPLICABLE FEDERAL AND
STATE SECURITIES LAWS.

 

VACCINOGEN,
INC.

COMMON
STOCK PURCHASE WARRANT

 

This
Common Stock Purchase Warrant (this “Warrant”) is issued as of this     
day of                   , 201
 , by Vaccinogen Inc., a Maryland corporation (the “Company”),
to The Abell Foundation, Inc., a Maryland corporation or permitted successors or assigns (the “Holder”).

 

1.           Issuance
of Warrant; Term; Price.

 

1.1           Issuance.
Pursuant to the terms of the Note and Warrant Purchase Agreement, dated as of October 26, 2011, between the Company and the Holder
(as the same has been and hereafter may be amended, supplemented or otherwise modified from time to time, the "Note
and Warrant Purchase Agreement”), the Holder has made a loan to
the Company evidenced by a promissory note in the maximum principal amount of [                               ]
Dollars ($                   )
dated as of [              ], 20  
(the “Note”). In consideration of the issuance of the Note, the receipt and sufficiency of which
are hereby acknowledged, the Company hereby grants to Holder the right to purchase, at any time and from time to time on and after
the date hereof until the Expiration Date (as defined below), up to [                     ]
fully paid and nonassessable shares (the “Warrant Shares”)
of Common Stock of the Company (the “Common Stock”)
on the terms and subject to the conditions set forth below. [Note: the number of Warrant Shares shall be equal to the sum of
(a) $1,100,000 divided by eighty-five percent (85%) of the lowest purchase price per share of Common Stock sold in the Company’s
the Venture Capital Financing (as defined in the Note and Warrant Purchase Agreement) plus (b) the sum of (i) 20,000 Warrant Shares
if the Note remains outstanding in whole or in part on August 31, 2013, (ii) 40,000 Warrant Shares if the Note remains outstanding
in whole or in part on September 30, 2013, (iii) 60,000 Warrant Shares if the Note remains outstanding in whole or in part on
October 31, 2013, (iv) 80,000 Warrant Shares if the Note remains outstanding in whole or in part on November 30, 2013, and (v)
100,000 Warrant Shares if the Note remains outstanding in whole or in part on December 31, 2013.]

 

    	 

    	 

    

 

1.2           Term.
This Warrant shall be exercisable at any time and from time to time in whole or in part from the date hereof to the earlier of'
(a) the ten- year anniversary of the date hereof; (b) the sale of all or substantially all of the Company’s assets; and
(c) any merger or consolidation of the Company in which the Company is not the surviving entity and the shareholders then owing
a majority of the outstanding equity interests in the Company no longer own or control a majority of such equity interests (the
earlier of such events being the “Expiration Date”) by delivery to the Company at its principal executive
offices o£ (i) this Warrant; (ii) the Purchase Form attached hereto as Exhibit A duly completed and executed; and
(iii) payment in accordance with Section 1,3 below. The Warrant Shares so purchased shall be issued to the Holder as the record
and beneficial owner of such Warrant Shares or to the Holder’s transferee as designated on the Purchase Form as of the close
of business on the date on which this Warrant shall have been surrendered and payment made for such Warrant Shares as aforesaid.

 

1.3.          Exercise
Price. Subject to adjustment as hereinafter provided, the exercise price (the “Warrant Price”) per
share for which all or any of the Warrant Shares may be purchased pursuant to the terms of this Warrant initially shall be equal
to $           [Note:
the Warrant Price per share shall equal eighty-five percent (85%) of the lowest price
per share of the Common Stock issued in the Venture Capital Financing.] The
Warrant Price shall be payable in cash or by certified or official bank check or by the cancellation of any present or future
indebtedness from the Company to the Holder hereof in a dollar amount equal to the purchase price of the Common Stock for which
the consideration is being given, or by surrendering for cancellation shares of capital stock of the Company which shares have
a fair market value equal to the purchase price of Common Stock for which the consideration is being given.

 

2.           Adjustment
of Warrant Price. Number and Kind of Shares. The Warrant Price and the number and kind of securities issuable upon the exercise
of this Warrant shall be subject to adjustment from time to time and the Company agrees to provide notice upon the happening of
certain events as follows.

 

2.1           Stock
Dividends Adjustment. In case at any time and from time to time after the date hereof, the holders of the Common Stock of the
Company (or any shares of stock or other securities at the time receivable upon the exercise of this Warrant) shall have received,
or, on or after the record date fixed for the determination of eligible stockholders, shall have become entitled to receive, without
payment therefor, other additional securities or other property (other than cash) of the Company by way of dividend or distribution,
then and in each case, the Holder shall, upon the exercise hereof, be entitled to receive, in addition to the number of Warrant
Shares receivable thereupon, and without payment of any additional consideration therefor, the amount of such other or additional
securities or other property (other than cash) of the Company which the Holder would hold on the date of such exercise had it been
the holder of record of such Warrant Shares on the date hereof and had thereafter, during the period from the date hereof to and
including the date of such exercise, retained such Warrant Shares and/or all other additional securities or other property receivable
by it as aforesaid during such period, giving effect to all adjustments called for during such period by this Section 2.

 

    	- 2 -

    	 

    

 

2.2           Reclassification
or Reorganization Adjustment. In case of any reclassification or change of the outstanding securities of the Company or of
any reorganization of the Company (or any other corporation the stock or securities of which are at the time receivable upon the
exercise of this Warrant) at any time and from time to time after the date hereof, and the Holder, upon the exercise hereof at
any time after the consummation of such reclassification, change or reorganization, shall be entitled to receive, in lieu of the
stock or other securities and property receivable upon the exercise hereof prior to such consummation, the stock or other securities
or property to which the Holder would have been entitled upon such consummation if such holder had exercised this Warrant immediately
prior thereto, all subject to further adjustment as provided in this Section 2.

 

2.3           Stock
Splits and Reverse Stock Splits. If at any time and from time to time after the date hereof, the Company shall subdivide or
otherwise change its outstanding shares of Common Stock into a greater number of shares, the Warrant Price in effect immediately
prior to such subdivision shall thereby be proportionately reduced and the number of shares receivable upon exercise of this Warrant
shall thereby be proportionately increased; and, conversely, if at any time and from time to time after the date hereof, the outstanding
number of shares of Common Stock shall be combined or otherwise changed into a smaller number of shares, the Warrant Price in effect
immediately prior to such combination shall thereby be proportionately increased and the number of shares receivable upon exercise
of this Warrant shall thereby be proportionately decreased.

 

2.4           Other
Impairment. The Company will not, by amendment of its articles of incorporation or bylaws or through any reorganization, transfer
of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out
of all such terms and conditions and in the taking of all such action as may be necessary or appropriate in order to protect the
rights of the Holder against impairment.

 

3.           No
Fractional Shares. No fractional shares of Common Stock will be issued in connection with any subscription hereunder. In lieu
of any fractional shares that would otherwise be issuable, the Company shall pay cash equal to the product of such fraction multiplied
by the fair market value of one share of Common Stock on the date of exercise, as determined in good faith by the Company’s
Board of Directors.

 

    	- 3 -

    	 

    

 

4.           No
Shareholder Rights. This Warrant as such shall not entitle Holder to any of the rights of a shareholder of the Company until
the Holder has exercised this Warrant in accordance with Section 6 hereof.

 

5.           Reservation
of Stock. The Company covenants that during the period this Warrant is exercisable, the Company will reserve from its authorized
and unissued Common Stock a sufficient number of shares thereof to provide for the issuance of Warrant Shares or other securities
upon the exercise of this Warrant. The Company agrees that its issuance of this Warrant shall constitute full authority to its
officers who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for Warrant
Shares or other securities upon the exercise of this Warrant.

 

6.           Exercise
of Warrant. This Warrant may be exercised by Holder by the surrender of this Warrant at the principal office of the Company,
accompanied by notice of and payment in full of the purchase price of the Warrant Shares the Holder elects to purchase hereunder.
As a condition to the Holder’s exercise of this Warrant, the Holder shall execute any agreement then in effect among the
holders of outstanding shares of capital stock of the Company. This Warrant shall be deemed to have been exercised immediately
prior to the close of business on the date of its surrender for exercise as provided above, and the person entitled to receive
the Warrant Shares or other securities and/or property issuable upon such exercise shall be treated for all purposes as the holder
of such Warrant Shares or other securities of record as of the close of business on such date. As promptly as practicable, the
Company shall issue and deliver to the person or persons entitled to receive the same a certificate or certificates for the number
of full Warrant Shares or other securities issuable upon such exercise, together with cash in lieu of any fraction of a share as
provided above. The Warrant Shares or other securities issuable upon exercise hereof shall, upon their issuance, be fully paid
and nonassessable. If this Warrant shall be exercised in part only, the Company shall, at the time of delivery of the certificate
representing the Warrant Shares in respect of which this Warrant has been exercised, make a notation on this Warrant stating the
Warrant Shares with respect to which this Warrant shall not have been exercised and this Warrant shall then be returned to the
Holder.

 

7.           Certificate
of Adjustment. Whenever the Warrant Price or number or type of securities issuable upon exercise of this Warrant is adjusted,
as herein provided, the Company shall promptly deliver to the record holder of this Warrant a certificate of an officer of the
Company setting forth the nature of such adjustment and a brief statement of the facts requiring such adjustment.

 

    	- 4 -

    	 

    

 

8.           Notice
of Proposed Transfers. This Warrant is transferable by the Holder hereof subject to compliance with this Section 8. Prior
to any proposed transfer of this Warrant or the Warrant Shares received on the exercise of this Warrant (the “Securities”),
unless there is in effect a registration statement under the Securities Act of 1933, as amended (the “Securities Act”),
covering the proposed transfer, the Holder thereof shall give written notice to the Company of such Holder’s intention to
effect such transfer. Each such notice shall describe the manner and circumstances of the proposed transfer in sufficient detail,
and shall, if the Company so requests, be accompanied (except in transactions in compliance with Rule 144) by either: (a) a written
opinion of legal counsel who shall be satisfactory to the Company acting reasonably addressed to the Company and satisfactory
in form and substance to the Company’s counsel acting reasonably, to the effect that the proposed transfer of the Securities
may be effected without registration under the Securities Act; or (b) a “no action” letter from the Securities Exchange
Commission (the “Commission”) to the effect that the transfer of such Securities without registration
will not result in a recommendation by the staff of the Commission that action be taken with respect thereto, whereupon the Holder
of the Securities shall be entitled to transfer the Securities in accordance with the terms of the notice delivered by the Holder
to the Company; provided, however, no such registration statement or opinion of counsel shall be necessary for a
transfer by a Holder to any affiliate of such Holder for no consideration, if the transferee agrees in writing to be subject to
the terms hereof to the same extent as if such transferee were the original Holder hereunder. Each certificate evidencing the
Securities transferred as above provided shall bear the appropriate restrictive legend set forth above, except that such certificate
shall not bear such restrictive legend if in the opinion of counsel for the Company acting reasonably such legend is not required
in order to establish compliance with any provisions of the Securities Act.

 

9.           Replacement
of Warrants. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of the Warrant, and in the case of any such loss, theft or destruction of the Warrant, on delivery of an indemnity
agreement or security satisfactory in form and amount to the Company acting reasonably, and reimbursement to the Company of all
reasonable expenses incidental thereto, and upon surrender and cancellation of the Warrant if mutilated, the Company will execute
and deliver, in lieu thereof, a new Warrant of like tenor.

 

10.         Dividends
and Distributions. So long as any part of this Warrant remains outstanding and unexercised, the Company will, upon the declaration
of a cash dividend upon its Common Stock or other distribution to the holders of its Common Stock and at least ten (10) days prior
to the record date, notify the Holder hereof of such declaration, which notice will contain, at a minimum, the following information:
(a) the date of the declaration of the dividend or distribution; (b) the amount of such dividend or distribution; (c) the record
date of such dividend or distribution; and (d) the payment date or distribution date of such dividend or distribution. The Holder
shall, upon the exercise hereof, be entitled to receive, in addition to the number of shares of Common Stock receivable thereupon,
and without payment of any additional consideration therefor, the amount of such other or additional securities or other property
(other than cash) of the Company which such Holder would hold on the date of such exercise had it been the holder of record of
such Common Stock on the date hereof and had thereafter, during the period from the date hereof to and including the date of such
exercise, retained such shares and/or all other additional securities or other property receivable by it as aforesaid during such
period, giving effect to all adjustments pursuant to Section 2.

 

    	- 5 -

    	 

    

 

11.         Miscellaneous.
This Warrant shall be governed by the laws of the State of Maryland. The headings in this Warrant are for purposes of convenience
of reference only, and shall not be deemed to constitute a part hereof. The invalidity or unenforceability of any provision hereof
shall in no way affect the validity or enforceability of any other provisions. All notices and other communications from the Company
to the Holder shall be delivered personally or mailed by first class mail, postage prepaid, or by facsimile to the address or facsimile
number furnished to the Company in writing by the last Holder who shall have furnished an address and facsimile number to the Company
in writing, and if mailed shall be deemed given three days after deposit in the U.S. Mail.

 

12.         Taxes.
The Company shall pay all issue taxes and other governmental charges (but not including any income taxes of a Holder) that may
be imposed in respect of the issuance or delivery of the Warrant Shares or any portion thereof.

 

13.         Amendment.
Any term of this Warrant may be amended with the written consent of the Company and the Holder. Any amendment effected in accordance
with this Section 13 shall be binding upon the Holder of this Warrant, each future holder of such Warrant, and the Company.

 

14.         Remedies.
In the event of any default or threatened default by the Company in the performance of or observance with any of the terms of this
Warrant, it is agreed that remedies at law are not and will not be adequate for the Holder and that such terms may be specifically
enforced by a decree for the specific performance of any agreement contained herein or by an injunction against a violation of
any of the terms hereof or otherwise.

 

15.         Facsimile
Signature. This Warrant may be executed by the Company in facsimile or pdf. form and upon receipt by the Holder of such faxed
executed copy of this Warrant, this Warrant shall be binding upon and enforceable against the Company in accordance with its terms.
The Company shall promptly forward to the Holder an original of the facsimile signed copy of this Warrant previously delivered
to Holder.

 

16.         Term.
The term of this Warrant (the “Term”), and the Holder’s right to exercise this Warrant, shall terminate
immediately upon the close of business (5:00 p.m., Eastern Standard Time) on the ten-year anniversary of the date hereof. Upon
termination of the Term, the Holder shall surrender this Warrant to the Company at the Company’s principal place of business.

 

    	- 6 -

    	 

    

 

IN WITNESS
WHEREOF, the undersigned officer of the Company has executed this Common Stock Purchase Warrant as of the date first above written.

 

	 	VACCINOGEN, INC.
	 	 	 
	 	By:	 
	 	Name:	Michael G. Hanna, Jr., Ph.D.
	 	Title: Chairman and Chief Executive Officer
	 	 	 
	 	By:	 
	 	Name: 	Andrew L. Tussing
	 	Title: President and Chief Operating Officer

  

    	- 7 -

    	 

    

 

EXHIBIT
A

PURCHASE
FORM

 

The
undersigned pursuant to the provisions set forth in the attached Warrant
(No.           ) hereby irrevocably elects to
purchase      shares of Warrant Shares covered by such Warrant and herewith makes
payment of ____________representing the full purchase price for such shares of Warrant Shares at the price per
share of Warrant Share provided for in such Warrant.

 

If
the shares of Warrant Shares are not to be issued in the name of the undersigned, the shares of Warrant Shares shall be issued
in the names of permitted assigns and in the number of units as follows:

 

	Name:	Name:
	 	 
	Address:	Address:
	 	 
	Tax ID
    #:	Tax ID #:
	 	 
	No. of Units:	No. of Units:
	 	 
	Dated:	 
	 	 
	Signature:	 
	 	 
	Print Name:	 
	 	 
	Address:	 

  

    	- 8 -Exhibit 10.1

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

MANUFACTURING SERVICES AGREEMENT

 

This
MANUFACTURING SERVICES AGREEMENT ("Agreement") is made this 9th day of September 2013,
by and between OSO BioPharmaceuticals Manufacturing, LLC (“OsoBio”), with a place of business at 4401
Alexander Blvd., Albuquerque, NM 87107, USA and Navidea Biopharmaceuticals, Inc. (“Navidea”),
having its principal place of business at 425 Metro Place North, Suite 450, Dublin, Ohio 43017,
USA.

 

		A.	OsoBio provides contract pharmaceutical development, manufacturing, packaging, analytical, and
sales and marketing services to the pharmaceutical industry.

 

		B.	Navidea has certain technology relating to the certain pharmaceutical
products and wants OsoBio to assist in the formulation, filling, packaging and testing on such products as provided in this
Agreement and the attachments hereto.

 

		C.	Navidea desires to engage OsoBio to provide certain services to Navidea in connection with the
processing of Navidea's Product (defined below); and OsoBio desires to provide such services pursuant to the terms and conditions
set forth in this Agreement.

 

NOW, THEREFORE, in
consideration of the mutual covenants, terms and conditions set forth below, the parties agree as follows:

 

ARTICLE 1

DEFINITIONS

 

The following terms
have the following meanings in this Agreement:

 

		1.1	"Affiliate(s)" means any corporation, firm, partnership or other entity which controls,
is controlled by or is under common control with a party. For purposes of this definition, "control" shall mean the ownership
of at least fifty percent (50%) of the voting share capital of such entity or any other comparable equity or ownership interest.

 

		1.2	“API” means the active pharmaceutical ingredient used in
the manufacture of the Product.

 

		1.3	"Applicable Laws" means all laws, ordinances, rules and regulations within the Territory
applicable to the Processing of the Product or any aspect thereof and the obligations of OsoBio or Navidea, as the context requires
under this Agreement, including, without limitation, (i) all applicable federal, state and local laws and regulations of each Territory;
(ii) the U.S. Federal Food, Drug and Cosmetic Act, and (iii) the Good Manufacturing Practices promulgated
by the Regulatory Authorities, as amended from time to time (“GMPs”).

 

    	 

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

		1.4	"Batch" means a specific quantity of a Product comprising a number of units of Product
mutually agreed upon between the parties, and that (a) is intended to have uniform character and quality within specified limits,
and (b) is Processed according to a single manufacturing order during the same cycle of Processing. Unless otherwise mutually agreed
by both parties, Batch size shall mean the targeted range of units used in the validation process, [*] vials.

 

		1.5	"Calendar Quarter" means a period of three (3) consecutive months commencing on January
1, April 1, July 1 or October 1 of any calendar year.

 

		1.6	“Calendar Year” means the period from January 1 to December 31 of each year.

 

		1.7	“Certificate of Analysis”
or “CofA” means
a certificate providing details about the quality and conformance to applicable quality assurance requirements relating specifically
to the result of testing a representative sample drawn from the specific batch or lot of material it is purported to represent.

 

		1.8	“Change Order” shall have the meaning set forth in Section 4.5(a).

 

		1.9	“Commencement Date” means the first date upon which
a Regulatory Authority approves OsoBio as a manufacturer of one of the Products; provided that such date shall not be earlier than
the date that a Regulatory Authority has granted marketing clearance for the Product.

 

		1.10	"Confidential Information" is as defined in Section 11.2.

 

		1.11	“Contract Year” means each consecutive twelve
(12) month period beginning on the Commencement Date.

 

		1.12	“Navidea Materials” shall have the meaning set forth in Article 12.

 

		1.13	“Defective Product” shall have the meaning set forth in Section 5.2.

 

		1.14	“Delayed Approval Fee” shall have the meaning set forth in Section 7.4.

 

		1.15	“Dispute” shall have the meaning set forth in Section 18.9.

 

		1.16	"Effective Date" means the date this Agreement was fully executed.

 

		1.17	“Facilities” means OsoBio’s facilities located in
Albuquerque, New Mexico, as set forth below:

 

    	2

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

	
        Manufacturing and Microbial Testing:
	Inspection, Testing, Packaging and Storage:
	4272 Balloon Park Rd NE	4401 Alexander Blvd NE
	Albuquerque, NM  87109	Albuquerque, NM  87107
	Analytical Testing:	Stability Testing:
	
        4200 Balloon Park Rd NE

        Albuquerque, NM 87109
	
        Not applicable to OsoBio.

         

        [*]

 

		1.18	“FDA” means the United States Food and Drug Administration, and any successor agency
thereto.

 

		1.19	“Firm Commitment” shall have the meaning set forth in Section 4.2.

 

		1.20	“Intellectual Property” means all intellectual property (whether or not patented),
including without limitation, patents, patent applications, know-how, trade secrets, copyrights, trademarks, designs, concepts,
technical information, manuals, standard operating procedures, instructions or specifications.

 

		1.21	“Minimum Requirement” shall have the meaning set forth in Section 4.1.

 

		1.22	“OsoBio Materials” shall have the meaning set forth in Article 12.

 

		1.23	"Process" or "Processing" shall mean the compounding, filling, producing, packaging
and labeling of the Raw Materials into Product in accordance with the Specifications and the terms and conditions set forth in
the Quality Agreement.

 

		1.24	"Processing Date" means the day on which the Product is to be first Processed by OsoBio.

 

		1.25	“Product" means the product
identified by the Specifications which may include unlabeled lyophilized vialed product and labeled
kits of finished Lymphoseek® product.

 

		1.26	“Purchase Order” shall have the meaning set forth in Section 4.3.

 

		1.27	“Raw Materials” means all raw materials, supplies, components, labeling and packaging
necessary to manufacture and ship the Product in accordance with the Specifications, as provided in Exhibit A, but not including
the API.

 

		1.28	“Regulatory Approval” shall have the meaning set forth in Section 7.4.

 

		1.29	"Regulatory Authority" means any governmental regulatory authority within the Territory
involved in regulating any aspect of the development, manufacture, market approval, sale, distribution, labeling, and packaging
or use of the Product.

 

    	3

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

		1.30	“Release of Product to Navidea” means the posting of all documents required for final
Product release by Navidea. Posting is done by OsoBio via a mutually agreed mechanism (i.e. secure electronic portal). This includes,
but is not limited to, relevant CofA’s, Batch records, and samples provided by OsoBio to Navidea. For purposes of clarity,
OsoBio does not perform final product release.

 

		1.31	“Review Period” shall have the meaning set forth in Section 5.1.

 

		1.32	“Rolling Forecast” shall have the meaning set forth in Section 4.2.

 

		1.33	“Sample” shall have the meaning set forth in Section 5.1.

 

		1.34	“Specifications” means the Product specifications set forth on Exhibit A, and
any procedures, requirements, standards, quality control testing, or any provisions of the Service Agreements that would impact
Product quality.

 

		1.35	"Term" shall have the meaning set forth in Section 15.1.

 

		1.36	“Territory” shall mean the United States of America, those countries regulated by the
European Medicines Agency (EMA), and any other country that the parties agree in writing to add to this Agreement from time to
time.

 

		1.37	“Unit Pricing" shall have the meaning set forth in Section 7.1.

 

		1.38	“Validation Batches” shall mean each Batch of Product manufactured by OsoBio which
is necessary to support the validation portion of Navidea’s NDA submission to the FDA.

  

ARTICLE 2 

VALIDATION, PROCESSING & RELATED
SERVICES

 

2.1           Validation
Services. OsoBio shall perform the qualification, validation and stability services described in Exhibit A,
and Exhibit B of this Agreement.

 

2.2           Supply
and Purchase of Product. During the Term, OsoBio shall be the primary supplier of manufacturing services for the Product and
shall Process the Products in accordance with the Specifications,
the Applicable Laws and the terms and conditions of this Agreement. Navidea shall purchase the Product from OsoBio in accordance
with the terms and conditions of this Agreement.

 

2.3           Other
Related Services. OsoBio shall provide other services upon terms and conditions agreed to by the parties in writing from time to
time.

 

    	4

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

ARTICLE 3 

MATERIALS

 

3.1           API.
Navidea shall supply to OsoBio for Processing, at Navidea's sole cost, the API and applicable reference standards in quantities
sufficient to meet Navidea's requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API
or reference standard to OsoBio for Processing, Navidea shall provide to OsoBio a copy of the API Material Safety Data Sheet (“MSDS”),
as amended, and any subsequent revisions thereto. Navidea shall supply the API, reference standards, and Certificate of Analysis
F.C.A. (Incoterms 2010) the Facilities no later than
sixty (60) days before the scheduled Processing Date upon which such API will be used by OsoBio. Upon receipt of the API, OsoBio
shall conduct testing of the API according to the specifications as agreed to by both parties. OsoBio shall use the API solely
and exclusively for Processing under this Agreement.

 

3.2           Raw
Materials. OsoBio shall be responsible for procuring, purchasing, inspecting and releasing adequate Raw Materials, at OsoBio’s
cost, as necessary to meet the Firm Commitment, unless otherwise agreed to by the parties in writing. Raw materials may be purchased
only from qualified suppliers. Navidea will be responsible for all costs associated with qualification of a supplier of a Raw Material
designated by Navidea not previously qualified by OsoBio. Unless a particular Raw Material can be replaced with the same raw material
from another supplier, OsoBio shall not be liable for any delay in delivery of Product if (i) OsoBio is unable to obtain, in a
timely manner, a particular Raw Material necessary to Process the Product, and (ii) OsoBio placed orders for such Raw Materials
promptly following receipt of Navidea’s Firm Commitment.

 

3.3           Artwork
and Packaging. Navidea shall provide or approve, prior to the procurement of applicable components, all artwork, advertising
and packaging information necessary to Process the Product. Such artwork, advertising and packaging information is and shall remain
the exclusive property of Navidea, and Navidea shall be solely responsible for the content thereof. Such artwork, advertising and
packaging information or any reproduction thereof may not be used by OsoBio following the termination of this Agreement, or during
the Term of this Agreement in any manner other than solely for the purpose of performing its obligations hereunder.

 

3.4           Reimbursement
for Materials. In the event of (i) a Specification change for any reason, (ii) termination or expiration of this Agreement
(other than a termination by Navidea under Section 15.2); or (iii) obsolescence of any Raw Material, Navidea shall bear the cost
of any unused Raw Materials, provided that OsoBio purchased such Raw Materials in quantities consistent with the first six months
of Navidea’s Rolling Forecast and any minimum purchase obligations required by the Raw Material supplier.

 

    	5

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

ARTICLE 4

MINIMUM COMMITMENT, PURCHASE ORDERS &
FORECASTS

 

4.1          Minimum
Requirement. During the term of the Agreement Navidea shall purchase from OsoBio a minimum of [*]
of its annual requirements for Product. 

 

4.1.1 In the event
that annual quantities do not exceed [*] Batches in Calendar
Year for which Navidea qualifies an additional contract
manufacturer, the minimum requirement of
this Section 4.1 will be waived for said Calendar Year.

 

4.1.2 In the event
(a) OsoBio fails to deliver Product for more than two
consecutive Calendar Quarters for which such
Product had been ordered and firm Purchase Order accepted by OsoBio in accordance with the requirements of Section 4.2
and such failure shall not be attributable to (i) any failure of performance by Navidea of any of its obligations under this agreement
or (ii) force majeure, or (b) without limiting any rights under
Section 15.2(a), OsoBio otherwise fails to cure any of its other material noncompliance with the terms of this Agreement within
180 days of formal notification of such non-complaince, Navidea shall be released from the minimum
requirement of this Section 4.1 for the remainder of the Term.

 

4.1.3 At the end
of each calendar year Navidea shall provide a statement of compliance
with this Section 4.1 as outlined in Exhibit D.

 

4.2          Forecast
and Purchase Order. On or before the first (1st) day of each Calendar
Quarter, beginning at least one (1) Calendar Quarter
prior to the anticipated Commencement Date, Navidea shall furnish to OsoBio a written twelve (12) month rolling forecast of the
quantities of Product that Navidea intends to order from OsoBio during such period ("Rolling Forecast"). The first six
(6) months of such Rolling Forecast shall constitute a firm and binding commitment to order for the quantities of Product specified
therein ("Firm Commitment") and the following six (6) months of the Rolling Forecast shall be non-binding, good faith
estimates. Navidea shall submit with the Rolling Forecast a binding, non-cancelable purchase order for the Firm Commitment portion
of the Processing, which specifies the actual number of Batches to be Processed, the approximate number of vials in each Batch,
and the specific requested delivery dates for each Batch ("Purchase Order"). Navidea
shall submit each Purchase Order to OsoBio at least ninety (90) days in advance of the Processing
Date requested in the Purchase Order. OsoBio shall notify Navidea in writing of acceptance each
Purchase Order within ten (10) days of receipt; provided that OsoBio
shall not be permitted to reject any Purchase Order unless such Purchase Order is not consistent with the terms of this Section
4.2 (i.e., not consistent with the applicable Firm Commitment amount or the ninety (90)-day lead time). If within the ten
(10)-day period after receipt of a Purchase Order OsoBio does not provide its notice of acceptance or rejection to Navidea, then
the Purchase Order shall be deemed to be accepted. In the event of a conflict between the terms of any Purchase Order and
this Agreement, this Agreement shall control unless OsoBio has accepted such conflicting terms in the written notice of acceptance
referenced in the preceding sentences.
Notwithstanding the foregoing, OsoBio shall use commercially reasonable efforts to supply Navidea with quantities of Product which
are in excess of the quantities specified in the Firm Commitment, subject to OsoBio's other supply commitments and manufacturing
and equipment capacity. Except as otherwise provided in this Section 4.2, no modification or amendment to this Agreement shall
be effected by or result from the receipt, acceptance, signing or acknowledgement of any party’s purchase orders, quotations,
invoices, shipping documents or other business forms containing terms or conditions in addition to or different from the terms
and conditions set forth in this Agreement.

 

    	6

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

4.4           OsoBio’s
Cancellation of Purchase Orders. In the event Navidea refuses or fails to make scheduled deliveries of the API as provided
in Section 3.1, OsoBio reserves the right to cancel all, or any part of, a Purchase Order upon written notice to Navidea and OsoBio
shall have no further obligations or liability with respect to such Purchase Order.

 

4.5           Unplanned
Delay or Elimination of Processing. OsoBio shall use diligent efforts to meet the Purchase Orders; provided that the foregoing
shall not limit OsoBio’s obligation to deliver Product on the delivery date specified in the relevant Purchase Order, nor
Navidea’s remedies in the event of a breach of such obligation under the terms and conditions of this Agreement. OsoBio shall
provide Navidea with as much advance notice as possible (and will use its best efforts to provide at least fifteen (15) days advance
notice where possible) if OsoBio determines that any Processing will be delayed or eliminated for any reason.

 

ARTICLE 5

TESTING; SAMPLES; RELEASE

 

5.1           Sample;
Testing; Acceptance.  Prior to delivering any shipment of Product, OsoBio shall provide Navidea
with a certificate of conformance and, additionally, in cases where OsoBio has performed any analytical testing of the Product,
a Certificate of Analysis, in each case certifying that the Product conforms in all material respects to the Specifications and
Applicable Laws. Navidea shall notify OsoBio within thirty (30) days following delivery of Product (or, in the case of any nonconformity
not reasonably susceptible to discovery upon receipt of the Product, within 30 days after discovery thereof by Navidea, but in
no event after the expiration date of the Product) to Navidea if Navidea has determined that such Product does not conform
to Specifications or Applicable Laws and shall provide OsoBio a sample of such non-conforming Product. OsoBio shall have 10 days
to advise Navidea in writing if it disagrees with Navidea’s claimed nonconformity. If OsoBio agrees that the Batch is non-conforming,
OsoBio shall, at its option, promptly re-perform the services in accordance with this Article,
or credit Navidea’s account for the invoiced price for such Product. If OsoBio does not agree with Navidea's determination
that such Product fails to meet the Specifications or Applicable Laws, then after reasonable efforts to resolve the disagreement,
either party may submit a sample of such Product to a mutually agreed upon independent third party laboratory to determine whether
the Product meets the Specifications and Applicable Laws. The independent party’s results shall be final and binding. In
the event that such evaluation determines that the Product does not conform to the Specifications or Applicable Laws, OsoBio shall
credit Navidea’s account for the invoiced price of such Product. Unless otherwise agreed to by the parties in writing, the
costs associated with such testing and review shall be borne by the non-prevailing party.

 

5.2           Replacement
of Defective Product. In accordance with the terms set forth in this Agreement, OsoBio shall, at its option, either (i) replace,
at its sole expense, all Product that does not comply with the Specifications (“Defective Product”) or (ii) credit
Navidea’s account for the invoiced price of such Defective Product. The obligation of OsoBio to replace Defective Product
in accordance with the Specifications or credit Navidea for such defective product shall be Navidea’s sole and exclusive
remedy under this agreement for Defective Product and is in lieu of any other warranty, express or implied.

 

    	7

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

5.3           Supply
of Material for Replacement Product. In the event OsoBio replaces Defective Product pursuant to Section 5.2, above, Navidea
shall supply OsoBio with sufficient quantities of the API at its sole cost as necessary for OsoBio complete such replacement, notwithstanding
Liability in Section 16.1. 

 

ARTICLE 6 

DELIVERY

 

6.1           Delivery.
OsoBio shall tender the Product for shipment, F.C.A. (Incoterms
2010) the Facility promptly following the Release of
Product to Navidea. Risk of loss or damage to the Product shall remain with OsoBio until the Product is loaded on the carrier’s
vehicle at the Facility, whereupon title and risk of loss or damage shall transfer to Navidea. Navidea shall be responsible for
all costs associated with shipment of the Product. Navidea shall designate carriers to ship the Product
and then designate the priority of such qualified carriers to OsoBio.

 

6.2           Failure
to Take Delivery. If Navidea or its designated agent fails to take delivery by the scheduled delivery date, or within 2
weeks of OsoBio’s release to Navidea, whichever is later, Navidea shall be invoiced on the last day of each month for
the stored Product and reasonable administration and storage costs. For each such Batch, or portion of a Batch,
of undelivered Product, Navidea agrees that: (i) Navidea has made a fixed commitment to purchase such Product, (ii)
risk of ownership for such Product passes to Navidea, (iii) such Product shall be on a bill and hold basis for legitimate
business purposes, (iv) if no delivery date is determined at the time of billing, OsoBio shall have the right to ship the
Product to Navidea within four months after billing, and (v) Navidea will be responsible for any decrease in market value of
such Product that relates to factors and circumstances outside of OsoBio’s control. Within five (5) days following a
written request from OsoBio, Navidea shall provide OsoBio with a letter confirming items (i) through (v) of this Section for
each Batch of undelivered Product.

 

ARTICLE 7 

PRICING AND PAYMENT

 

7.1           Pricing.
Navidea shall pay to OsoBio the unit pricing set forth on Exhibit B (“Unit Pricing”) for all Product. In addition,
Navidea shall pay OsoBio for certain regulatory support services as set forth on Exhibit B. In the event Navidea
requests any other services, OsoBio shall provide a written quote of the fee for such additional services and Navidea shall advise
OsoBio whether it wishes to have such additional services performed by OsoBio.

 

    	8

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

7.2           Price
Increase.  OsoBio may implement an increase in the Unit Pricing for the Product
once annually in accordance with the total percentage change in the Producer Price Index, Pharmaceutical Preparations (Series ID
PCU325412325412) as published by the U.S. Department of Labor, Bureau of Labor Statistics (“PPI”) over the twelve (12)
month period preceding the date of such price increase, provided, however that, notwithstanding the actual change in the PPI, if
OsoBio’s cost for any Raw Material changes by more than five percent (5%), OsoBio shall modify the Unit Pricing to account
for such cost differential. In the event of an increase tied to a change in OsoBio’s cost of Raw Materials, OsoBio shall
provide Navidea copies of invoices evidencing the increased cost of such Raw Materials. Notwithstanding the foregoing, OsoBio shall
not increase the Unit Price more frequently than once in any twelve (12) month period and may not increase the Unit Price for any
undelivered Product that is the subject of a Purchase Order issued within the preceding twelve (12) months.

 

7.3           Taxes;
Duty. All taxes, duties and other amounts assessed on the Raw Materials, API or the Product prior to or upon sale to Navidea
are the responsibility of Navidea, and Navidea shall reimburse OsoBio for any such taxes, duties or other expenses paid by OsoBio.

 

7.4           Product
Approval. Notwithstanding the terms set forth above, Navidea shall use its commercially reasonable efforts to expedite
and obtain all regulatory approvals necessary for OsoBio to commence production at the Facility (“Regulatory Approvals”).

 

7.5           Payment
Terms. OsoBio shall invoice Navidea for all Product upon shipment of the Product pursuant to Section 6.1, and payment for such
invoices shall be due within thirty (30) days after the date of such invoice. Each such invoice shall, to the extent applicable,
identify the Purchase Order number, quantities, Unit Price, freight charges, and the total amount to be remitted by Navidea. Navidea
shall pay all undisputed invoices within 30 days of the date of the invoice. Any undisputed amounts not paid by Navidea when due
under this Agreement, shall accrue interest at the rate of one and one-half percent (11⁄2%) per month until paid in full.

 

ARTICLE 8 

CHANGES TO SPECIFICATIONS

 

All Specifications
and any changes thereto agreed to by the parties from time to time shall be in writing, dated and signed by the parties. No change
in the Specifications shall be implemented by OsoBio, whether requested by Navidea or requested or required by any Regulatory Authority,
until the parties have agreed in writing to such change, the implementation date of such change, and any increase or decrease in
fees associated with such change. OsoBio shall respond promptly to any request made by Navidea for a change in the Specifications,
and both parties shall use commercially reasonable, good faith efforts to agree to the terms of such change in a timely manner.
As soon as possible after a request is made for any change in Specifications, OsoBio shall notify Navidea of the fees associated
with such change. Navidea shall pay all fees associated with such agreed upon changes.

 

ARTICLE 9

QUALITY & REGULATORY MATTERS

 

9.1           Quality
Agreement. This Agreement hereby incorporates the Quality Agreement between OsoBio and Navidea dated 11 April, 2013 as attached
to this Agreement as Exhibit C. The Quality Agreement shall in no way determine liability or financial responsibility of
the parties for the responsibilities set forth therein. In the event of a conflict between the terms of this Agreement and the
Quality Agreement, this Agreement shall control except with respect to matters relating to compliance with GMPs and related regulations,
in which case, the Quality Agreement will control.

 

    	9

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

9.2           Regulatory
Compliance. Navidea shall be solely responsible for all permits and licenses required by any Regulatory
Authority with respect to the Product under this Agreement, including any product licenses, applications
and amendments in connection therewith. OsoBio will be responsible to maintain all permits and licenses required by any Regulatory
Authority with respect to the Facility or the Processing of the Product. Each party intends and commits to cooperate to satisfy
all Applicable Laws relating to their activities under this Agreement.

 

9.3           Regulatory
Authority Inspection. OsoBio hereby agrees to advise Navidea promptly, but not later than within two business days, of any proposed
or, scheduled or unannounced inspection of the Product or Processing by any Regulatory Authority and will, to the extent not prohibited
by Applicable Law, permit Navidea to be present during any such inspection. If Navidea is not present during such an inspection,
OsoBio shall promptly provide a report of the results of the inspection to Navidea.

 

9.4           Audit.
Navidea or its designated representative shall have the right during normal business hours, and upon reasonable notice to OsoBio,
to inspect and audit in a reasonable manner those portions of the Facilities in which Processing is conducted in order to ensure
OsoBio’s compliance with its obligations under this Agreement.

 

9.5           Recall.
In the event OsoBio believes a recall, field alert, Product withdrawal or field correction may be necessary with respect to any
Product provided under this Agreement, OsoBio shall immediately notify Navidea in writing. OsoBio will not act to initiate a recall,
field alert, Product withdrawal or field correction without the express prior written approval of Navidea, unless otherwise required
by Applicable Laws or upon advice of legal counsel. In the event Navidea believes a recall, field alert, Product withdrawal or
field correction may be necessary with respect to any Product provided under this Agreement, Navidea shall immediately notify OsoBio
in writing and OsoBio shall provide all necessary cooperation and assistance to Navidea. Navidea shall bear the cost of, and shall
reimburse OsoBio for expenses incurred in connection with, any recall, field alert, Product withdrawal or field correction related
to the Product unless such recall, field alert, Product withdrawal or field correction is caused primarily by OsoBio’s breach
of its obligations under this Agreement or Applicable Laws or its negligence or willful misconduct, in which case, such cost shall
be borne by OsoBio. For purposes hereof, such cost shall be limited to reasonable, actual and documented administrative costs incurred
by Navidea for such recall, withdrawal or correction, and replacement of the Defective Product to be recalled, in accordance with
Article 5. 

 

ARTICLE 10 

REPRESENTATIONS, WARRANTIES AND COVENANTS

 

10.1         OsoBio.
OsoBio represents, warrants and covenants to Navidea that:

 

    	10

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

A. At the time of delivery
of the Product as provided in Section 6.1, such Product will conform to and will have been Processed in conformance with the Specifications
and Applicable Laws.

 

B. It has all necessary
authority and all right, title and interest in and to any Intellectual Property necessary to Process the Product or that is otherwise
required to perform its obligations under this Agreement.

 

C.
It will comply with the Quality Agreement and all Applicable
Laws during its performance under this Agreement and its use
of any materials or API provided by Navidea under this Agreement.

 

D.
It will obtain and maintain for each Facility all permits, licenses and approvals required for OsoBio to Process and supply all
Products in compliance with the terms of this Agreement and all Applicable Laws.

 

E.
It will not ship the Product if the batch record for a particular Batch of Product indicates that the Product does not comply with
the Specifications or Applicable Laws, or if the Product has expired.

 

F.
Prior to releasing any Batch of Product, it will review all
Product specific validation records and confirm that the Product is in compliance with Applicable Laws.

 

G. All Products delivered
to Navidea shall (1) comply with the specifications and be produced in accordance with current Good Manufacturing Practices;
(2) be free and clear of any and all encumbrances, liens, security interests or other third party claims; and (3) not be adulterated
or misbranded within the meaning of the U.S. Food, Drug and Cosmetic Act or any similar law or regulation of applicable Regulatory
Authorities.

 

H. It has not been
debarred by the FDA or other Regulatory Authorities, and has not been convicted of a crime that could lead to such debarment.

 

I. It will not employ,
contract with or retain any person directly or indirectly to perform services under this Agreement if such a person is debarred
by the FDA under 21 U.S.C. § 335(a) or disqualified as described in 21 C.F.R. §312.170. In the event that OsoBio becomes
aware of or receive notice of the debarment or disqualification of any person providing services to under this Agreement, then
OsoBio agrees to notify Navidea immediately.

 

10.2        Navidea.
Navidea represents and warrants to OsoBio that:

 

A.           The
Navidea-supplied API will comply with all applicable Specifications, will have been produced in compliance with the Applicable
Laws;

 

B.           It
has all necessary authority and all right, title and interest in and to any Intellectual Property related to each Product or that
is otherwise required to perform its obligations under this Agreement;

 

    	11

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

C.           All
artwork and packaging provided by Navidea to OsoBio under Section 3.3 shall comply with all Applicable Laws;

 

D.           It
has provided all safe handling instructions, health and environmental information and material safety
data sheets applicable to the Product or to the API, except as disclosed to OsoBio in writing by Navidea in sufficient time for
review and training by OsoBio prior to delivery; 

 

E.           All
Product delivered to Navidea by OsoBio will be held, used and/or disposed of by Navidea in accordance with all Applicable Laws;
and

 

F.           It
will comply with all Applicable Laws applicable to Navidea’s performance under this Agreement and its use of any materials
or Products provided by OsoBio under this Agreement.

 

G.           It
will not release the Product if the batch record for a particular Batch of Product indicates that the Product does not comply with
the Specifications or Applicable Laws.

 

H.           Prior
to releasing any Batch of Product, it will review all Product specific validation records and confirm that the Product is in compliance
with Applicable Laws.

 

10.3        Mutual.
Each party hereby represents and warrants to the other party that:

 

A.           Existence
and Power. Such party (1) is duly organized, validly existing and in good standing under the laws of the state in which it
is organized, (2) has the power and authority and the legal right to own and operate its property and assets, and to carry on its
business as it is now being conducted, and (3) is in compliance with all requirements of Applicable Laws, except to the extent
that any noncompliance would not materially adversely affect such party's ability to perform its obligations under the Agreement;

 

B.           Authorization
and Enforcement of Obligations. Such party (1) has the power and authority and the legal right to enter into this Agreement
and to perform its obligations hereunder and (2) has taken all necessary action on its part to authorize the execution and delivery
of this Agreement and the performance of its obligations hereunder.

 

C.           Execution
and Delivery. This Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid,
binding obligation, enforceable against such party in accordance with its terms;

 

D.           No
Consents. All necessary consents, approvals and authorizations of all Regulatory Authorities and other persons required to
be obtained by such party in connection with the Agreement have been obtained; and

 

E.           No
Conflict. The execution and delivery of this Agreement and the performance of such party's obligations hereunder (1) do not
conflict with or violate any requirement of Applicable Laws; and (2) do not materially conflict with, or constitute a material
default or require any consent under, any material contractual obligation of such party.

 

    	12

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

10.4         Limitations.
THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE 10 ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE
BY EACH PARTY TO THE OTHER AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER,
INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.

 

ARTICLE 11 

CONFIDENTIAL INFORMATION

 

11.1         Mutual
Obligation. OsoBio and Navidea agree that they will not disclose the other party’s Confidential Information (defined
below) to any third party without the prior written consent of the other party except as required by law, regulation or court or
administrative order (including without limitation the Securities Act of 1933, the Securities Exchange Act of 1934, and the regulations
promulgated thereunder); provided, however, that prior to making any such legally required disclosure, the party making such disclosure
shall give the other party as much prior notice of the requirement for and contents of such disclosure as is practicable under
the circumstances. Notwithstanding the foregoing, each party may disclose the other party’s Confidential Information to any
of its Affiliates that (A) need to know such Confidential Information for the purpose of performing under this Agreement, (B) are
advised of the contents of this Article, and (C) agree to be bound by the terms of this Article. Each receiving party shall use
the disclosing party’s Confidential Information solely for the purpose of carrying out the receiving party’s obligations
under this Agreement.

 

11.2         Definition.
As used in this Agreement, the term “Confidential Information” includes all such information furnished by OsoBio or
Navidea, or any of their respective representatives or Affiliates, to the other or its representatives or Affiliates, whether furnished
before, on or after the date of this Agreement and furnished in any form, including but not limited to written, verbal, visual,
electronic or in any other media or manner. Confidential Information includes all proprietary technologies, know-how, trade secrets,
discoveries, inventions and any other Intellectual Property (whether or not patented), analyses, compilations, business or technical
information and other materials prepared by either party, or any of their respective representatives, containing or based in whole
or in part on any such information furnished by the other party or its representatives. Notwithstanding the foregoing, Navidea
Confidential Information shall include the Process, all Master Batch Records, and all Production Batch Records related to the manufacture
and release of the Product. Confidential Information also includes the existence of this Agreement and its terms, provided that
Navidea may disclose the existence of this Agreement and its terms to a third party and/or the third party’s advisors in
connection with an investment in Navidea, acquisition of or merger with Navidea, loan to Navidea, licensing transaction related
to the Product or other commercial agreement related to the sale, marketing or distribution of the Product, provided that Navidea
requires said third party to enter into a confidentiality agreement on terms no less restrictive than those contained herein and
that Navidea also remains responsible for any disclosure by said third party.

 

    	13

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

11.3         Exclusions.
Notwithstanding Section 11.2, Confidential Information does not include information that (A) is or becomes generally available
to the public or within the industry to which such information relates other than as a result of a breach of this Agreement, or
(B) is already known by the receiving party at the time of disclosure as evidenced by the receiving party’s written records,
or (C) becomes available to the receiving party on a non-confidential basis from a source that is entitled to disclose it on a
non-confidential basis, or (D) was or is independently developed by or for the receiving party without reference to the Confidential
Information, as evidenced by the receiving party’s written records.

 

11.4         No
Implied License. The receiving party will obtain no right of any kind or license under any Intellectual Property rights of
a disclosing party by reason of this Agreement. All Confidential Information will remain the sole property of the party disclosing
such information or data.

 

11.5         Return
of Confidential Information. Upon termination of this Agreement, the receiving party shall, upon request, promptly return within
thirty (30) days all such information, including any copies thereof, and cease its use or, at the request of the disclosing party,
shall promptly destroy the same and certify such destruction to the disclosing party; except for a single copy thereof, which may
be retained for the sole purpose of determining the scope of the obligations incurred under this Agreement.

 

11.6         Survival.
The obligations of this Article 11 will terminate five (5) years from the expiration of this Agreement.

 

ARTICLE 12

INTELLECTUAL PROPERTY

 

12.1 Rights in Materials. All OsoBio Materials,
including without limitation, all improvements, developments, derivatives or modifications to the OsoBio Materials, shall be owned
exclusively by OsoBio. All Navidea Materials, including, without limitation, all improvements, developments, derivatives or modifications
to the Navidea Materials shall be owned exclusively by Navidea. For purposes hereof, “OsoBio Materials” means all OsoBio
proprietary information, intellectual property, and developments (including, all patents, patent applications, know-how, inventions,
designs, concepts, improvements, technical information, manuals, instructions or specifications), owned, licensed or used by OsoBio
in developing, formulating, manufacturing, filling, processing or packaging of liquid solutions or pharmaceuticals and the packaging
equipment, processes or methods of packaging, or any improvements to any of the foregoing, including any container, pouch, vial,
ampoule or other form of liquid container developed by OsoBio. For purposes hereof, “Navidea Materials” means all proprietary
information, intellectual property and developments owned, developed, licensed or used by Navidea relating to the API and Product,
including, without limitation, patents, patent applications, know-how, inventions, designs, concepts, improvements, technical information,
trademarks or trade names.

 

    	14

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

12.2 Inventions. If OsoBio or its
agents or employees make any invention, improvement or modification (whether or not patentable) to the Product or the use thereof
(exclusive of methods of Processing) in the course of providing services under this Agreement, OsoBio shall promptly disclose such
invention, improvement or modification to Navidea and assign and/or cause its agents or employees to assign all rights, title and
interest in such invention, improvement or modification to Navidea. OsoBio shall execute such further documents and take such further
actions as are reasonable or necessary to fully vest in Navidea such rights, title and interest.

 

ARTICLE 13

INDEMNIFICATION

 

13.1         Indemnification
by OsoBio. Subject to the limitation of liability provisions of Section 16, OsoBio shall indemnify and hold harmless
Navidea, its Affiliates, and their respective directors, officers, employees and agents (“Navidea Indemnitees”) from
and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses
(including reasonable attorneys’ fees) in connection with any suit, demand or action by any third party (“Losses”)
arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this Agreement or
(B) any gross negligence or willful misconduct by OsoBio, except to the extent that any of the foregoing arises out of or results
from any Navidea Indemnitee’s negligence, willful misconduct or breach of this Agreement.

 

13.2         Indemnification
by Navidea. Navidea shall indemnify and hold harmless OsoBio, its Affiliates, and their respective directors, officers,
employees and agents (“OsoBio Indemnitees”) from and against all Losses arising out of or resulting from (A) any
breach of its representations, warranties or obligations set forth in this Agreement; (B) any manufacture, sale, promotion,
distribution, use of or exposure to the Product or any Navidea-supplied API, or third-party sourced diluent,
incorporated into the Product including, without limitation, product liability or strict
liability; (C) Navidea's exercise of control over the Processing of the Product to the extent that Navidea's instructions or
directions violate Applicable Law; (D) any actual or alleged infringement or violation by the API or Product of any third
party Intellectual Property rights provided by Navidea; or (F) any gross negligence or willful misconduct by Navidea, except
to the extent that any of the foregoing arises out of or results from any OsoBio Indemnitee’s gross negligence, willful
misconduct or breach of this Agreement.

 

13.3         Indemnification
Procedures. All indemnification obligations in this Agreement are conditioned upon the party seeking indemnification: (A) promptly
notifying the indemnifying party of any claim or liability of which the party seeking indemnification becomes aware (including
a copy of any related complaint, summons, notice or other instrument); provided, however, that failure to provide such notice within
a reasonable period of time shall not relieve the indemnifying party of any of its obligations hereunder except to the extent the
indemnifying party is prejudiced by such failure; and (B) reasonably cooperating with the indemnifying party in the defense of
any such claim or liability (at the indemnifying party's expense). The indemnifying party may,
in its sole discretion, assume and conduct the legal defense of the indemnified person in, and the settlement of, any suit that
could result in claims under this Section 13.3; provided, however , that the indemnifying party will not, in defense of any such
suit, except with the consent of the indemnified person, consent to the entry of any judgment or enter into any settlement which
does not include, as an unconditional term thereof, the giving by the claimant or plaintiff to the indemnified person of a release
from all liability in respect thereof. If the indemnifying party assumes the defense and settlement of a suit, the indemnified
person may elect to participate in, but not control, such defense and settlement through counsel of its choosing and at its own
expense.

 

    	15

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

ARTICLE 14 

INSURANCE

 

During
the Term, each party shall, at its own cost and expense, obtain and maintain in full force and effect the following insurance:
(i) with respect to OsoBio only, Commercial General Liability
insurance with per-occurrence and general aggregate limits of not less than [*]; (ii) Products and Completed Operations
Liability Insurance with per-occurrence and general aggregate limits of not less than [*]; (iii) Workers’ Compensation
and Employer’s Liability Insurance with statutory limits for Workers’ Compensation and Employer’s Liability insurance
limits of not less than [*]; (iv) with respect to OsoBio only,
Professional Services Errors & Omissions Liability Insurance with per claim and aggregate limits of not less than [*]
covering sums that OsoBio becomes legally obligated to pay as damages resulting from claims made by Navidea for errors or omissions
committed in the conduct of the services outlined in the Agreement;
and (v) with respect to Navidea only, All Risk Property Insurance, including transit coverage, in an amount equal to full replacement
value covering Navidea’s property while it is at the Facility. In the event that any of the required policies of insurance
are written on a claims made basis, then such policies shall be maintained during the entire Term
and for a period of not less than three (3) years following the termination or expiration of this Agreement. Upon
request of a party, the other party shall furnish evidence of insurance for the above noted policies applicable
to such other party. Each insurance policy that is required under this Article 14 shall be obtained from an insurance carrier
with an A.M. Best rating of at least A- VII.

 

ARTICLE 15 

TERM AND TERMINATION

 

15.1        Term.
This Agreement shall commence on the Effective Date and shall continue until December 31, 2016,
unless earlier terminated under Section 15.2 below (the "Term"). After December 31, 2016,
this Agreement shall automatically renew for additional two (2) year periods, unless written notice of intent to cancel
the agreement is provided by either party at least twelve (12) months prior to the expiration of the initial term or any.

 

15.2        Termination
by Either Party.

 

(a)          Material
Breach. Either party may terminate this Agreement effective upon sixty (60) days prior written notice to the other party, if
the other party commits a material breach of this Agreement and fails to cure such breach by the end of such sixty (60) day period;
provided, however, that failure to pay all undisputed invoices under this Agreement within ninety (90) days after such payments
are due (as set forth in Section 8.5) shall constitute cause for immediate termination of this Agreement, or at OsoBio’s
discretion, OsoBio shall be relieved of any further obligation to perform under this Agreement until all outstanding payments are
brought current.

 

    	16

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

(b)          Bankruptcy.
Either party may terminate this Agreement effective upon written notice to the other party, if the other party becomes insolvent
or admits in writing its inability to pay its debts as they become due, files a petition for bankruptcy, makes an assignment for
the benefit of its creditors or has a receiver, trustee or other court officer appointed for its properties or assets.

 

15.3        Duties
Upon Termination. In the event of any termination, other than a termination by either party as a result of a material breach
by the other, OsoBio shall complete delivery of any Product in accordance with any Purchase Order open as of the date notice of
termination is given hereunder. In the event of any termination, OsoBio shall promptly, after completion of any deliveries required
by the immediately preceding sentence, return to Navidea (i) any remaining inventory of API or other materials received from Navidea
or Navidea’s suppliers, (ii) all packaging components paid for by Navidea, (iii) all remaining inventories of the Product;
and (iv) any Product or material being stored for Navidea, at Navidea’s expense. OsoBio shall have no obligation to return
the foregoing until all outstanding invoices to Navidea have been paid in full.

 

ARTICLE 16 

LIMITATIONS OF LIABILITY

 

16.1        OSOBIO’S
LIABILITY FOR ANY AND ALL CLAIMS FOR LOST, DAMAGED OR DESTROYED API OR OTHER NAVIDEA-SUPPLIED MATERIALS, WHETHER OR NOT SUCH API
OR NAVIDEA-SUPPLIED MATERIALS ARE INCORPORATED INTO FINISHED PRODUCT OR DEFECTIVE PRODUCT SHALL BE LIMITED TO [*].

 

16.2        OSOBIO’S
TOTAL LIABILITY UNDER THIS AGREEMENT SHALL IN NO EVENT EXCEED THE TOTAL FEES PAID BY NAVIDEA TO OSOBIO FOR THE SERVICES OR BATCH
OF PRODUCT GIVING RISE TO SUCH LIABILITIES, CLAIMS, OR OBLIGATIONS.

 

16.3        NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL LOSSES, DAMAGES,
COSTS OR EXPENSES OF ANY NATURE WHATSOEVER ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, INCLUDING WITHOUT LIMITATION,
LOSS OF REVENUES, PROFITS OR DATA, OR PENALTIES ARISING UNDER THIRD PARTY CONTRACTS, WHETHER IN CONTRACT OR TORT, EVEN IF SUCH
PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. NOTWITHSTANDING
THE FOREGOING, NOTHING IN THIS SECTION 16.3 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY
UNDER ARTICLE 13, OR DAMAGES AVAILABLE FOR BREACHES OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 11.

 

    	17

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

ARTICLE 17 

NOTICE

 

All notices and other communications hereunder
shall be in writing and shall be deemed given: (A) when delivered personally; (B) when delivered by facsimile transmission (receipt
verified); (C) when received or refused, if mailed by registered or certified mail (return receipt requested), postage prepaid;
or (D) when delivered if sent by express courier service,

 

to the parties at the following addresses
(or at such other address for a party as shall be specified by like notice; provided, that notices of a change of address shall
be effective only upon receipt thereof):

 

	To Navidea:	 	Navidea Biopharmaceuticals, Inc.
	 	 	425 Metro Place North, Suite 450
	 	 	Dublin, OH 43017
	 	 	Attn.:  President
	 	 	Facsimile:  (614) 793-7522
	 	 	 
	With a copy to:	 	Navidea Biopharmaceuticals, Inc.
	 	 	425 Metro Place North, Suite 450
	 	 	Dublin, OH 43017
	 	 	Attn.:  CFO
	 	 	Facsimile:  (614) 793-7522
	 	 	 
	To OsoBio:	 	OSO BioPharmaceuticals Manufacturing, LLC
	 	 	4401 Alexander Blvd. NE
	 	 	Albuquerque, NM 87107
	 	 	Attn: President/CEO
	 	 	Facsimile: (505) 923-1611
	 	 	 
	With a copy to:	 	
        OSO BioPharmaceuticals Manufacturing, LLC

        4401 Alexander Blvd. NE

	 	 	Albuquerque, NM 87107
	 	 	Attn: Contracts Manager
	 	 	Facsimile: (505) 923-1611

 

ARTICLE 18 

MISCELLANEOUS

 

18.1         Entire
Agreement; Amendments. This Agreement, including the attachments, Project Plans and any amendments thereto, constitutes the
entire understanding between the parties and supersede any contracts, agreements or understanding (oral or written) of the parties
with respect to the subject matter hereof. No term of this Agreement may be amended or modified except upon written agreement signed
by a duly authorized officer of each party, unless otherwise expressly provided in this Agreement.

 

    	18

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

18.2         Captions.
The captions in this Agreement are for convenience only and are not to be interpreted or construed as a substantive part of
this Agreement

 

18.3         Further
Assurances. The parties agree to execute, acknowledge and deliver such further instruments and to take all such other
incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

 

18.4         No
Waiver. Failure by either party to insist upon strict compliance with any term of this Agreement in any one or more
instances will not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent
failure.

 

18.5         Severability.
If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining
terms of this Agreement will continue in full force and effect.

 

18.6         Independent
Contractors. The relationship of the parties is that of independent contractors, and neither party will incur any debts or
make any commitments for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement is
intended to create or will be construed as creating between the parties the relationship of joint ventures, co-partners, employer/employee
or principal and agent.

 

18.7         Successors
and Assigns. This Agreement will be binding upon and inure to the benefit of the parties, their successors and permitted assigns.
Neither party may assign this Agreement, in whole or in part, without the prior written consent of the other party, except that
either party may, without the other party's consent, assign this Agreement to an Affiliate or to a successor to substantially all
of the business or assets of the assigning company.

 

18.8         Governing
Law. This Agreement shall be governed by and construed under the laws of the State of Delaware, excluding its conflicts of
law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.

 

18.9         Alternative
Dispute Resolution. If any dispute arises between the parties relating to this Agreement, including the breach, termination
or validity thereof (“Dispute”), such Dispute shall be presented to the respective presidents or senior executives
of OsoBio and Navidea for their consideration and resolution. All negotiations pursuant to the preceding sentence will be confidential
and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence. If such parties cannot
reach a resolution of the Dispute, then such Dispute shall be finally resolved by binding alternative dispute resolution in accordance
with the then existing Rules for Non-Administered Arbitration of the CPR Institute for Dispute Resolution, 366 Madison Avenue,
New York, NY 10017 (“CPR Rules”) by three independent and impartial arbitrators, of whom each party shall designate
one, with the third arbitrator appointed as provided in the CPR Rules. The arbitration shall be governed by the Federal Arbitration
Act, 9 U.S.C. §§1 et seq. and judgment upon the award rendered by the arbitrator(s) may be entered by any court having
jurisdiction thereof, subject, however, to the right of a party to appeal such award under the CPR Arbitration Appeal Procedure.
.. Arbitration shall be conducted in the jurisdiction of the defendant party. Each party is required to continue to perform
its obligations under this Agreement pending final resolution of any dispute arising out of or relating to this Agreement, unless
to do so would be impossible or impracticable under the circumstances, and provided that the provisions of this Section 18.9 shall
not be deemed to be a waiver of any right of termination under Section 15.2. Notwithstanding anything in this Section 18.9 to the
contrary, the parties shall be entitled to seek at any time during a Dispute injunctive relief or other equitable remedies with
respect to any Dispute from any court of competent jurisdiction.

 

    	19

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

18.10         Prevailing
Party. In any dispute resolution proceeding between the parties in connection with this Agreement, tribunal shall have the
authority to award and apportion costs, including reasonable attorneys’ fees and other costs incurred by the parties, taking
into account the circumstances of the case, the conduct of the parties during the proceeding, and the result.

 

18.11         Counterparts.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall
constitute an original.

 

18.12         Publicity.
Neither party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated
hereby without the other party's express prior written consent, except as required under applicable law or by any governmental
agency, in which case the party required to make the press release or public disclosure shall use commercially reasonable efforts
to obtain the approval of the other party as to the form, nature and extent of the press release or public disclosure prior to
issuing the press release or making the public disclosure.

 

18.13         Survival.
The rights and obligations of the parties under Articles 11 (Confidential Information), 12 (Intellectual Property), 13 (Indemnification),
14 (Insurance) to the extent expressly stated therein, 16 (Limitations of Liability), 17 (Notice), 18 (Miscellaneous), and Section
15.3 (Duties Upon Termination), shall continue notwithstanding expiration or termination of this Agreement.

 

18.15         Force
Majeure. Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this
Agreement be terminable or cancelable (except as provided in this Section 18.15) by reason of, any delay or default in such party’s
performance hereunder, if such default or delay is caused by events beyond such party’s reasonable control including, but
not limited to, acts of God, regulation or law or other action or failure to act of any government or agency thereof, war or insurrection,
civil commotion, destruction of production facilities or materials by earthquake, fire, flood or storm, labor disturbances, epidemic,
or failure of suppliers, public utilities or common carriers; provided however, that the party seeking relief hereunder shall promptly
notify the other party of such cause(s). A party that invokes this section shall use all commercially reasonable endeavors to reinstate
its ongoing obligations to the other; provided that if the cause(s) shall continue unabated for one hundred eighty (180) days,
then the party that has not invoked this Section to excuse its delay or nonperformance may terminate this Agreement, subject to
the duties set forth in Section 15.3.

 

    	20

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

18.16       No
Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express
their mutual intent, and no rules of strict construction will be applied against any party.

 

IN WITNESS WHEREOF,
the parties have caused their duly authorized representative to execute this Agreement effective as of the date first written above.

 

	OsoBio	 	Navidea
	 	 	 
	OSO BioPharmaceuticals Manufacturing, LLC	 	Navidea Biopharmaceuticals, Inc.
	 	 	 
	By:	/s/ Milton Boyer	 	By:	/s/ Brent L.
    Larson
	Name:	Milton Boyer	 	Name:	Brent L. Larson
	Its:	President	 	Its:	EVP & CFO

 

    	21

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

EXHIBIT A

SPECIFICATIONS

 

SPECIFICATION
FOR LYMPHOSEEK VIAL, 250mcg

 

	Characteristic	 	Specification (Limits)	 	Test Method
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	 	 	 	 	 
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]
	[*]	 	[*]	 	[*]

 

a
[*]

b
[*]

c
[*]

d
[*]

    	22

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

EXHIBIT
B

UNIT PRICING, FEES 

 

	UNIT PRICING
	Product	 	Dosage Form	 	Initial Unit Price
	Lymphoseek Vial, 250mcg	 	Lyophilized, multi-dose vial	 	[*]1
	 	 	 	 	 

 

1 Unit pricing is based
upon a [*] unit Batch size

 

	ADDITIONAL FEES
	 	 	 
	
        Annual Product Maintenance Fee

        Includes:

        ·

        ·    Annual
Product Reviews

        ·    Copies
        of Documents (Routine – Batch record related or Product specific)

        ·    Notification
        of Updates to Drug Master File (DMF)

        ·    Product
Licenses

        ·    Navidea
        Complaints

        Does not Include:

        ·    Rest
        of World (ROW) filings or additional countries after 1st filing

        ·    CMC Services
        after 1st filing

        ·    All
        additional countries Additional Annual, CBE or Prior Approval filings with respect to changes to facilities
        and equipment initiated or required by Navidea

        •Labeling Changes
        requested by Navidea
	[*] per year	
        Payable upon the Effective Date and once annually, on the anniversary
        date of this Agreement and continuing following termination of this Agreement until all Product Processed under this Agreement
        has expired.

         

 

Items
excluded will be billed @ [*] to [*]
per hour plus any actual external or material resources and mutually agreed and approved in writing by both parties.

    	23

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

EXHIBIT C

FORM OF QUALITY AGREEMENT

 

(To be appended upon execution of QAA for
execution copies of Supply Agreement)

 

    	24

    	 

    

 

Confidential Treatment – Asterisked
material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential
treatment.

 

EXHIBIT D

 

STATEMENT OF COMPLIANCE FOR MINIMUM
QUANITIES OF LYMPLHOSEEK SOURCED BY NAVIDEA BIOPHARMACEUTICALS, INC.

 

The quantities purchased in calendar
year 20__ represent a minimum of [*] of the annual requirements
of Product purchased by Navidea from all sources.

 

Signed:

 

Name:

 

Title:

 

Date:

    	25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]